$16.81
+0.24%Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Wall Street analysts project that SLP stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 56.00, with estimates ranging from a low of 47.00 to a high of 65.00.
The consensus 1-year price target stands at 56.00, with estimates ranging from a low of 47.00 to a high of 65.00.
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Positive outlook with reasonable agreement. Analysts generally optimistic about prospects with manageable uncertainty.
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Flat growth suggests market maturity or near-term challenges offsetting expansion efforts.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Generally favorable outlook with reasonable growth prospects and analyst support.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Reasonable estimate spread indicates general agreement with normal forecast variance.
Positive analyst consensus with strong growth expectations and forecast confidence.
Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Limited coverage may indicate reduced institutional interest or information availability.
Reasonable estimate spread indicates general agreement with normal forecast variance.
Generally favorable outlook with reasonable growth prospects and analyst support.
Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.
Significant contraction projectedโmajor business challenges or industry disruption likely.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Mixed signalsโsome positive indicators offset by concerns about growth or uncertainty.
Significant contraction projectedโmajor business challenges or industry disruption likely.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Mixed signalsโsome positive indicators offset by concerns about growth or uncertainty.
Solid growth trajectory indicates healthy business performance and competitive positioning.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
During the last 12 months, insiders have purchased $2.20M and sold $1.11M worth of SLP shares, resulting in $1.10M of net buying activity.
0
0.00
33.0K
533.28K
-533K
-$533K
0
0.00
0
0.00
+0
+$0
137.5K
2.20M
20.9K
322.44K
+1.9M
+$1.88M
0
0.00
14.0K
250.56K
-251K
-$251K
Oconnor Shawn
Officer: Chief Executive Officer
$801K
Frederick William W
Officer: Evp/Cfo
$521K
Dibella John Anthony Ii
Officer: Chief Revenue Officer
$441K
Fiedler-Kelly Jill
Officer: President, Services Solutions
$441K
Woltosz Walter S
Director, 10 Percent Owner:
$1.02M
Lavange Lisa
Director
$38K
Dibella John Anthony Ii
Officer: Chief Revenue Officer
$28K
Fiedler-Kelly Jill
Officer: President, Services Solutions
$17K
Moderately bullish with $1.10M net buying. Insiders show cautious optimism through measured share purchases.
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Heavy recent selling activity. Recent insider sales notably exceed purchasesโmay warrant investigation into company developments.
4 insider buyers and 4 sellers. Equal participation suggests mixed or neutral insider views.
Broad-based insider buying: When multiple insiders independently decide to purchase shares, it often reflects genuine confidence rather than coordinated optics. This pattern deserves attention, especially if buying followed a price decline.
Continue your SLP research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.